<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               17. PATIENT COUNSELING INFORMATION<BR>               <BR>                  Patients should be informed of the following information before initiating therapy with CELEBREX and periodically during the course of ongoing therapy.<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.1	Medication Guide<BR>                     <BR>                        Patients should be informed of the availability of a Medication Guide for NSAIDs that accompanies each prescription dispensed, and should be instructed to read the Medication Guide prior to using CELEBREX.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.2	Cardiovascular Effects<BR>                     <BR>                        Patients should be informed that CELEBREX may cause serious CV side effects such as MI or stroke, which may result in hospitalization and even death.  Patients should be informed of the  the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and to seek immediate medical advice if they observe any of these signs or symptoms. [ ].<BR>                                    see<BR>                                        Warnings and Precautions (5.1)<BR>                           <BR>                        <BR>                        Patients should be informed that CELEBREX can lead to the onset of new hypertension or worsening of preexisting hypertension, and that CELEBREX may impair the response of some antihypertensive agents.  Patients should be instructed on the proper follow up for monitoring of blood pressure.  [ ].<BR>                                    see and<BR>                                        Warnings and Precautions (5.2)<BR>                              Drug Interactions (7.4)<BR>                           <BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.3	Gastrointestinal Effects<BR>                     <BR>                        Patients should be informed that CELEBREX can cause gastrointestinal discomfort and more serious side effects, such as ulcers and bleeding, which may result in hospitalization and even death.  Patients should be informed of the signs and symptoms of ulcerations and bleeding, and to seek immediate medical advice if they observe any signs or symptoms that are indicative of these disorders, including epigastric pain, dyspepsia, melena, and hematemesis. [ ].<BR>                                    see<BR>                                        Warnings and Precautions (5.4)<BR>                           <BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.4	Hepatic Effects<BR>                     <BR>                        Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms).  Patients should be instructed that they should stop therapy and seek immediate medical therapy if these signs and symptoms occur [ ].<BR>                                    see ,<BR>                                        Warnings and Precautions (5.5)<BR>                              Use in Specific Populations (8.6)<BR>                           <BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.5	Adverse Skin Reactions<BR>                     <BR>                        Patients should be informed that CELEBREX is a sulfonamide and can cause serious skin side effects such as exfoliative dermatitis, SJS, and TEN, which may result in hospitalizations and even death.  Although serious skin reactions may occur without warning, patients should be informed of the signs and symptoms of skin rash and blisters, fever, or other signs of hypersensitivity such as itching, and seek immediate medical advice when observing any indicative signs or symptoms.<BR>                        Patients should be advised to stop CELEBREX immediately if they develop any type of rash and contact their physician as soon as possible.<BR>                        Patients with prior history of sulfa allergy should not take CELEBREX [ ].<BR>                                    see<BR>                                        Warnings and Precautions (5.8)<BR>                           <BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.6	Weight Gain and Edema<BR>                     <BR>                        Long-term administration of NSAIDs including CELEBREX has resulted in renal injury. Patients at greatest risk are those taking diuretics, ACE-inhibitors, angiotensin II antagonists, or with renal or liver dysfunction, heart failure, and the elderly [ ].<BR>                                    see ,<BR>                                        Warnings and Precautions (5.3<BR>                              , 5.6)<BR>                              Use in Specific Populations (8)<BR>                           <BR>                        <BR>                        Patients should be instructed to promptly report to their physicians signs or symptoms of unexplained weight gain or edema following treatment with CELEBREX [ ].<BR>                                    see<BR>                                        Warnings and Precautions (5.3)<BR>                           <BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.7	Anaphylactoid Reactions<BR>                     <BR>                        Patients should be informed of the signs and symptoms of an anaphylactoid reaction (e.g., difficulty breathing, swelling of the face or throat).  Patients should be instructed to seek immediate emergency assistance if they develop any of these signs and symptoms [ ].<BR>                                    see<BR>                                        Warnings and Precautions (5.7)<BR>                           <BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.8	Effects During Pregnancy<BR>                     <BR>                        Patients should be informed that in late pregnancy CELEBREX should be avoided because it may cause premature closure of the ductus arteriosus [ ].<BR>                                    see ,<BR>                                        Warnings and Precautions (5.9)<BR>                              Use in Specific Populations (8.1)<BR>                           <BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.9	Preexisting Asthma<BR>                     <BR>                        Patients should be instructed to tell their physicians if they have a history of asthma or aspirin-sensitive asthma because the use of NSAIDs in patients with aspirin-sensitive asthma has been associated with severe bronchospasm, which can be fatal.  Patients with this form of aspirin sensitivity should be instructed not to take Celebrex.  Patients with preexisting asthma should be instructed to seek immediate medical attention if their asthma worsens after taking Celebrex  [ ].<BR>                                    see<BR>                                        Warnings and Precautions (5.13)<BR>                           <BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>